Sub Heading

Clinical Trials Details

Safety and Efficacy of Intravenous Cemiplimab Plus BNT116 Versus Cemiplimab Alone in Advanced Non-Small Cell Lung Cancer in Adult Participants With PD-L1 = 50%

IRB Protocol Number
Regeneron 2045

Clinical Trial Categories

  • Lung Cancer
Contact
Clinical Trials at 910-715-2200
How to Participate

Eligibility:

  • Non small cell lung cancer, stage IIIB-IV
  • No prior treatment for recurrent or metastatic disease
  • PD-L1 expression  ≥50%
  • No actionable mutations

Contact Us

For more information on participating in a clinical trial, contact us at 910-715-2200 or talk to your doctor.